Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
November 06 2023 - 7:30AM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company pursuing development of targeted therapies for oncology,
today announced that it will release its financial results for the
third quarter 2023 before the market opens on Monday, November 13,
2023. Management will host a webcast/teleconference the same day at
8:00 a.m. Eastern Time to discuss the results and provide a
corporate update.
Webcast and Conference Call
Information
To participate in the teleconference, domestic callers should
dial 1-877-407-0784 or1-201-689-8560. A live webcast presentation
can also be accessed using this weblink:
https://viavid.webcasts.com/starthere.jsp?ei=1639042&tp_key=7d2827005c.
A replay of the webcast will be available on the Celcuity website
following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on
development of targeted therapies for treatment of multiple solid
tumor indications. The company's lead therapeutic candidate is
gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism
of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that
target PI3K or mTOR alone or together. A Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant
with or without palbociclib in patients with HR+/HER2- advanced
breast cancer is currently enrolling patients. More detailed
information about the VIKTORIA-1 study can be found at
ClinicalTrials.gov . A Phase 1b/2 clinical trial, CELC-G-201,
evaluating gedatolisib in combination with darolutamide in patients
with metastatic castration resistant prostate cancer, is expected
to be initiated in the first quarter of 2024. The company's
CELsignia companion diagnostic platform is uniquely able to analyze
live patient tumor cells to identify new groups of cancer patients
likely to benefit from already approved targeted therapies. Further
information about Celcuity can be found at Celcuity.com . Follow us
on LinkedIn and Twitter .
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc. Brian Sullivan,
bsullivan@celcuity.com Vicky Hahne,
vhahne@celcuity.com (763) 392-0123
ICR Westwicke Maria Yonkoski,
maria.yonkoski@westwicke.com (203) 682-7167
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Apr 2024 to May 2024
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From May 2023 to May 2024